Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Annals of Oncology(2022)10.1016/j.annonc.2022.01.074Source: DataRank Database

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 5.7. It has been cited 265 times, with 100 citing works in its 1-hop citation network.

N/A

5.7DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access265 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02899299

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 32.78)OA: hybridTopics (39)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 15%Citation Network 85%

Base Score Contribution

0.838

From this paper's citation signal

Citation Network Contribution

4.8

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations
Allergy202244 citations14 referencesContributes 0.272
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia
Journal of Thoracic Oncology20247 citations8 referencesContributes 0.260
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso
Journal of Thoracic Oncology202334 citations15 referencesContributes 0.237
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology2022387 citations27 referencesContributes 0.221
Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials
Journal of Chemotherapy202217 citations14 referencesContributes 0.206

Authors (20)

Arnaud Scherpereel ORCID,Robin Cornelissen ORCID,Youssef Oulkhouir,Laurent Greillier ORCID,Kaplan Ma ORCID

Live enrichment

PubMed:35124183 OpenAlex:https://openalex.org/W4210792133

Bristol-Myers Squibb

Ono Pharmaceutical

FWCI

32.78

Citation Percentile

1.0%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.annalsofoncology.org/article/S0923753422000837/pdf

HYBRIDhttp://www.annalsofoncology.org/article/S0923753422000837/pdf

publisherhttp://www.annalsofoncology.org/article/S0923753422000837/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0923753422000837?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0923753422000837?httpAccept=text/plain

Fields of Study

Occupational and environmental lung diseasesPleural and Pulmonary DiseasesCancer Immunotherapy and BiomarkersMedicineAdultAntineoplastic Combined Chemotherapy ProtocolsHumansIpilimumabMesothelioma, MalignantNivolumabProgression-Free Survival

MeSH Terms

IpilimumabNivolumabProgression-Free SurvivalMesothelioma, MalignantAdultAntineoplastic Combined Chemotherapy ProtocolsHumans

Keywords

MedicineNivolumabIpilimumabInternal medicinePemetrexedHazard ratioOncologyChemotherapyResponse Evaluation Criteria in Solid TumorsAdverse effectCancerPhases of clinical researchConfidence intervalImmunotherapyCisplatinCTLA-4PD-L1Overall SurvivalFirst-lineImmune Checkpoint InhibitorsDual Immunotherapy

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

10.6084/m9.figshare.23700554.v1figshare

Additional file 1 of Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

10.6084/m9.figshare.23700554figshare

Additional file 1 of Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy

10.6084/m9.figshare.24580410.v1figshare

Additional file 1 of Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy

10.6084/m9.figshare.24580410figshare

Additional file 1 of Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

10.6084/m9.figshare.26682484.v1figshare

Additional file 1 of Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

10.6084/m9.figshare.26682484figshare

Additional file 2 of Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy

10.6084/m9.figshare.24580501figshare

Additional file 2 of Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy

10.6084/m9.figshare.24580501.v1figshare